Ligand Pharmaceuticals Q1 2024 Adj EPS $3.84 Beats $0.78 Estimate, Sales $30.978M Beat $27.924M Estimate
Ligand Pharmaceuticals Q1 2024 Adj EPS $3.84 Beats $0.78 Estimate, Sales $30.978M Beat $27.924M Estimate
Ligand Pharmicals第一季度经调整后的每股收益为3.84美元，超过预期的0.78美元，销售额为3097.8万美元超过2792.4万美元的预期
Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $3.84 per share which beat the analyst consensus estimate of $0.78 by 392.31 percent. This is a 68.42 percent increase over earnings of $2.28 per share from the same period last year. The company reported quarterly sales of $30.978 million which beat the analyst consensus estimate of $27.924 million by 10.94 percent. This is a 29.56 percent decrease over sales of $43.979 million the same period last year.
Ligand Pharmicals（纳斯达克股票代码：LGND）公布的季度收益为每股3.84美元，比分析师普遍预期的0.78美元高出392.31％。这比去年同期每股收益2.28美元增长了68.42％。该公司公布的季度销售额为3,0978万美元，比分析师普遍预期的2792.4万美元高出10.94％。这比去年同期的4397.9万美元的销售额下降了29.56％。